Mesa Nilda
CIK: 0001756697
Associated companies
Transaction History
| UTHR | ▲ Buy | Option Exercise | 130 | $14K | 9/14/2026 | View on chart |
| UTHR | ▼ Sell | Open Market | 130 | $66K | 9/14/2026 | View on chart |
| UTHR | ▼ Sell | Open Market | 98 | $50K | 9/14/2026 | View on chart |
| UTHR | ▲ Buy | Option Exercise | 650 | $0 | 7/9/2026 | View on chart |
| UTHR | ▼ Sell | Open Market | 258 | $150K | 5/12/2026 | View on chart |
| UTHR | ▼ Sell | Open Market | 187 | $90K | 12/9/2025 | View on chart |
| UTHR | ▲ Buy | Option Exercise | 590 | $0 | 7/25/2025 | View on chart |
| UTHR | ▼ Sell | Open Market | 645 | $187K | 6/24/2025 | View on chart |
| UTHR | ▼ Sell | Open Market | 255 | $91K | 12/30/2024 | View on chart |
| UTHR | ▼ Sell | Open Market | 224 | $92K | 11/8/2024 | View on chart |
| UTHR | ▲ Buy | Option Exercise | 900 | $0 | 7/13/2024 | View on chart |
| UTHR | ▼ Sell | Open Market | 266 | $85K | 6/25/2024 | View on chart |
| UTHR | ▼ Sell | Open Market | 325 | $77K | 3/27/2024 | View on chart |
| UTHR | ▼ Sell | Open Market | 605 | $148K | 12/19/2023 | View on chart |
| UTHR | ▼ Sell | Open Market | 383 | $85K | 9/13/2023 | View on chart |
| UTHR | ▲ Buy | Option Exercise | 880 | $0 | 7/7/2023 | View on chart |
| UTHR | ▼ Sell | Open Market | 374 | $80K | 5/5/2023 | View on chart |
| UTHR | ▼ Sell | Open Market | 290 | $78K | 11/7/2022 | View on chart |
| UTHR | ▼ Sell | Open Market | 400 | $83K | 9/29/2022 | View on chart |
| UTHR | ▼ Sell | Open Market | 850 | $179K | 9/28/2022 | View on chart |
| UTHR | ▲ Buy | Option Exercise | 1,080 | $0 | 7/8/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
United Therapeutics Settles Litigation, Market Reassesses Valuation
United Therapeutics has settled a litigation that impacts its pulmonary hypertension business. The settlement resets competition in that market and has led analysts to question whether the stock is undervalued. The move may prompt a reassessment of the company’s value by investors.
United Therapeutics Settles Litigation, Market Reassesses Valuation. United Therapeutics has settled a litigation that impacts its pulmonary hypertension business. The settlement resets competition in that market and has led analysts to question whether the stock is undervalued. The move may prompt a reassessment of the company’s value by investors.